- Home
- FEBO vs CERO Comparison
FEBO vs CERO Comparison
Compare FEBO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- CERO
- Stock Information
- Founded
- FEBO 1993
- CERO 2017
- Country
- FEBO Hong Kong
- CERO United States
- Employees
- FEBO N/A
- CERO N/A
- Industry
- FEBO
- CERO
- Sector
- FEBO
- CERO
- Exchange
- FEBO Nasdaq
- CERO Nasdaq
- Market Cap
- FEBO 8.0M
- CERO 9.6M
- IPO Year
- FEBO 2023
- CERO N/A
- Fundamental
- Price
- FEBO $0.70
- CERO $5.92
- Analyst Decision
- FEBO
- CERO Strong Buy
- Analyst Count
- FEBO 0
- CERO 2
- Target Price
- FEBO N/A
- CERO $45.00
- AVG Volume (30 Days)
- FEBO 431.0K
- CERO 258.5K
- Earning Date
- FEBO 10-24-2025
- CERO 08-22-2025
- Dividend Yield
- FEBO N/A
- CERO N/A
- EPS Growth
- FEBO N/A
- CERO N/A
- EPS
- FEBO N/A
- CERO N/A
- Revenue
- FEBO $17,110,653.00
- CERO N/A
- Revenue This Year
- FEBO N/A
- CERO N/A
- Revenue Next Year
- FEBO N/A
- CERO N/A
- P/E Ratio
- FEBO N/A
- CERO N/A
- Revenue Growth
- FEBO 11.58
- CERO N/A
- 52 Week Low
- FEBO $0.61
- CERO $5.41
- 52 Week High
- FEBO $8.50
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- FEBO 41.81
- CERO 26.39
- Support Level
- FEBO $0.68
- CERO $8.07
- Resistance Level
- FEBO $0.76
- CERO $7.60
- Average True Range (ATR)
- FEBO 0.11
- CERO 0.48
- MACD
- FEBO 0.01
- CERO -0.17
- Stochastic Oscillator
- FEBO 12.58
- CERO 14.74
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.